Capricor Therapeutics (NASDAQ:CAPR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
Separately, HC Wainwright reiterated a “buy” rating and issued a $8.60 target price (up previously from $6.50) on shares of Capricor Therapeutics in a research note on Friday, January 26th.
Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.07. The firm had revenue of $0.31 million during the quarter, compared to the consensus estimate of $1.00 million. The company’s quarterly revenue was down 58.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.29) EPS. equities research analysts anticipate that Capricor Therapeutics will post -0.54 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of CAPR. Virtu KCG Holdings LLC lifted its stake in shares of Capricor Therapeutics by 571.9% in the second quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock worth $149,000 after buying an additional 152,614 shares in the last quarter. Wells Fargo & Company MN bought a new position in shares of Capricor Therapeutics in the third quarter worth approximately $107,000. Jane Street Group LLC bought a new position in shares of Capricor Therapeutics in the third quarter worth approximately $190,000. Finally, Belpointe Asset Management LLC bought a new position in shares of Capricor Therapeutics in the third quarter worth approximately $249,000. Hedge funds and other institutional investors own 4.05% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Downgrades Capricor Therapeutics (CAPR) to Hold” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/02/zacks-investment-research-downgrades-capricor-therapeutics-capr-to-hold.html.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.